NASDAQ : OKYO

OKYO Pharma Limited — Company profile

Healthcare · Biotechnology · United Kingdom

Last price 1.5 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 78.72M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Details

NameOKYO Pharma Limited
SectorHealthcare
IndustryBiotechnology
Employees5
Founded2007
Ipo Date2022-05-17
CeoRobert Dempsey
CountryUnited Kingdom
ExchangeNASDAQ
Fiscal YearApril - March
Reporting CurrencyUSD
Ipo Price4.00
IsinGG00BMFG5F62
CusipG6724L116
Cik1849296
Sic2836

Key executives

NameTitle
Robert J. Dempsey M.B.A.Chief Executive Officer and Executive Director
Keeren ShahChief Financial Officer
Dr. Rajkumar Patil Ph.D.Chief Scientific Officer
Dr. Gary S. Jacob Ph.D.Chief Development Officer and Director
Dr. Flavio Mantelli M.D., Ph.D.Chief Medical Officer
Michael Paul BeckFounder

Contact

Address35a Albemarle St, Floor 2, London, W1S 4JE, United Kingdom
Phone44 20 7495 2379
Websitehttps://okyopharma.com